Zevra Therapeutics KMPH Stock
Zevra Therapeutics Price Chart
Zevra Therapeutics KMPH Financial and Trading Overview
Zevra Therapeutics stock price | 5.81 USD |
Previous Close | 5.83 USD |
Open | 5.83 USD |
Bid | 0 USD x 800 |
Ask | 0 USD x 1400 |
Day's Range | 5.79 - 5.97 USD |
52 Week Range | 4 - 6.92 USD |
Volume | 64.13K USD |
Avg. Volume | 229.68K USD |
Market Cap | 200.47M USD |
Beta (5Y Monthly) | 2.158647 |
PE Ratio (TTM) | N/A |
EPS (TTM) | 0 USD |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 22.33 USD |
KMPH Valuation Measures
Enterprise Value | 142.34M USD |
Trailing P/E | N/A |
Forward P/E | -8.544118 |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 18.699139 |
Price/Book (mrq) | 2.1368148 |
Enterprise Value/Revenue | 13.276 |
Enterprise Value/EBITDA | -8.031 |
Trading Information
Zevra Therapeutics Stock Price History
Beta (5Y Monthly) | 2.158647 |
52-Week Change | -14.95% |
S&P500 52-Week Change | -4.19% |
52 Week High | 6.92 USD |
52 Week Low | 4 USD |
50-Day Moving Average | 5.32 USD |
200-Day Moving Average | 5.27 USD |
KMPH Share Statistics
Avg. Volume (3 month) | 229.68K USD |
Avg. Daily Volume (10-Days) | 355.86K USD |
Shares Outstanding | 34.5M |
Float | 31.26M |
Short Ratio | 5.87 |
% Held by Insiders | 10.29% |
% Held by Institutions | 17.68% |
Shares Short | 1.45M |
Short % of Float | 4.22% |
Short % of Shares Outstanding | 4.20% |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor | 1:16 |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2021 |
Most Recent Quarter (mrq) | September 30, 2022 |
Next Fiscal Year End | December 31, 2022 |
Profitability
Profit Margin | 0% |
Operating Margin (ttm) | -171.91% |
Gross Margin | 97.58% |
EBITDA Margin | -165.31% |
Management Effectiveness
Return on Assets (ttm) | -8.97% |
Return on Equity (ttm) | -31.23% |
Income Statement
Revenue (ttm) | 10.72M USD |
Revenue Per Share (ttm) | 0.31 USD |
Quarterly Revenue Growth (yoy) | 46.30% |
Gross Profit (ttm) | 26.59M USD |
EBITDA | -17723000 USD |
Net Income Avi to Common (ttm) | -35225000 USD |
Diluted EPS (ttm) | -0.91 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 75.89M USD |
Total Cash Per Share (mrq) | 2.2 USD |
Total Debt (mrq) | 17.06M USD |
Total Debt/Equity (mrq) | 18.19 USD |
Current Ratio (mrq) | 10.098 |
Book Value Per Share (mrq) | 2.719 |
Cash Flow Statement
Operating Cash Flow (ttm) | -15103000 USD |
Levered Free Cash Flow (ttm) | -10898625 USD |
Profile of Zevra Therapeutics
Country | United States |
State | FL |
City | Celebration |
Address | 1180 Celebration Boulevard |
ZIP | 34747 |
Phone | 888 958 1253 |
Website | https://zevra.com |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | 24 |
Zevra Therapeutics, Inc., a rare disease therapeutics company, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company utilizes its Ligand Activated Therapy technology to generate improved prodrug versions of FDA-approved drugs, as well as to generate prodrug versions of existing compounds that may have applications for new disease indications. Its prodrug product candidate pipeline is focused on the high need areas of attention deficit hyperactivity disorder, stimulant use disorder, and CNS rare diseases, including idiopathic hypersomnia (IH). The company's lead product candidate KP1077, which is under Phase II clinical trial for the treatment of IH and narcolepsy, is based on its prodrug of d-methylphenidate, known as serdexmethylphnidate. It is also developing KP879, a prodrug product candidate for the treatment of stimulant use disorder and is under Phase I clinical trial. In addition, the company has received FDA approval for AZSTARYS, a new once-daily treatment for attention deficit hyperactivity disorder in patents age six years and older, and for APADAZ, an immediate-release combination product containing benzhydrocodone, a prodrug of hydrocodone, and acetaminophen. Zevra Therapeutics, Inc. has collaboration and license agreement with KVK-Tech, Inc. and Commave Therapeutics SA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. Zevra Therapeutics, Inc. was incorporated in 2006 and is headquartered in Celebration, Florida.
Q&A For Zevra Therapeutics Stock
What is a current KMPH stock price?
Zevra Therapeutics KMPH stock price today per share is 5.81 USD.
How to purchase Zevra Therapeutics stock?
You can buy KMPH shares on the NasdaqGS exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Zevra Therapeutics?
The stock symbol or ticker of Zevra Therapeutics is KMPH.
Which industry does the Zevra Therapeutics company belong to?
The Zevra Therapeutics industry is Biotechnology.
How many shares does Zevra Therapeutics have in circulation?
The max supply of Zevra Therapeutics shares is 34.5M.
What is Zevra Therapeutics Price to Earnings Ratio (PE Ratio)?
Zevra Therapeutics PE Ratio is 0.00000000 now.
What was Zevra Therapeutics earnings per share over the trailing 12 months (TTM)?
Zevra Therapeutics EPS is 0 USD over the trailing 12 months.
Which sector does the Zevra Therapeutics company belong to?
The Zevra Therapeutics sector is Healthcare.
Zevra Therapeutics KMPH included in indexes
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
---|
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
---|---|---|---|---|---|---|---|
{{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
NASDAQ Composite IXIC | 16175.09 USD — |
-1.62
|
3.94B USD — | 16125.33 USD — | 16341.46 USD — | — - | 3.94B USD — |
NASDAQ Global Select Market Com NQGS | 7876.03 USD — |
-1.61
|
— — | 7852.08 USD — | 7955.84 USD — | — - | — — |
NASDAQ Biotechnology NBI | 4195.13 USD — |
-2.14
|
— — | 4174.1 USD — | 4266.29 USD — | — - | — — |
NASDAQ HealthCare IXHC | 958.68 USD — |
-2.07
|
— — | 954.08 USD — | 972.42 USD — | — - | — — |
NASDAQ Biotechnology Total Retu XNBI | 4501.69 USD — |
-2.14
|
— — | 4479.13 USD — | 4578.05 USD — | — - | — — |
NASDAQ Capital Market Composite RCMP | 114.55 USD — |
-2.27
|
— — | 114.09 USD — | 116.72 USD — | — - | — — |
Stlmt ID NASDAQ Biotechnology NBX | 4604.4 USD — |
-2.98
|
— — | 4555.41 USD — | 4917.8 USD — | — - | — — |
NASDAQ Composite Total Return I XCMP | 19659.36 USD — |
-1.62
|
— — | 19598.88 USD — | 19861.56 USD — | — - | — — |
- {{ link.label }} {{link}}